Clinical Trial Update: Pilot Study of Autologous Chimeric Switch Receptor Modified T Cells in Recurrent Glioblastoma Multiforme [Phase 1]

View source ↗

Summary

Phase 1 pilot trial evaluating autologous chimeric switch receptor-modified T cells for recurrent glioblastoma multiforme.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Multiforme

Drugs mentioned

• Autologous Chimeric Switch Receptor Modified T Cells

Snippet

Sponsor: Beijing Sanbo Brain Hospital | Conditions: Glioblastoma Multiforme | Phase 1 | Status: UNKNOWN